J. Cadranel - Concepedia

Author

J. Cadranel

Also Known As

Arnaud Bourdin, Christophe Hennequin, F. Couturaud, Florence Tubach, Iryna Bukreyeva, J CADRANEL, J Cadranel, J L Cadranel, J. CADRANEL, J. Cadranel

390

Publications

12.3K

Citations

H-Index

Concepts

All Affiliations

Sorbonne Université Hôpital Tenon Assistance Publique – Hôpitaux de Paris Inserm Université Paris Cité

About

J. Cadranel is an author at Sorbonne Université specializing in medicine, pathology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	40	6.2K
2	Health Sciences	6	6	290
3	Public Health	3	3	265
4	Cell Biology	2	2	196
5	Cellular Physiology	1	1	131

J. Cadranel

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline Andrew J. Ullmann, José María Aguado, David W. Denning, Clinical Microbiology and Infection Diagnostic MycologyDiagnosisPathologyClinical MycologyExecutive Summary	2018	1.5K
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features Aryeh Fischer, Kevin M. Brown, J. Cadranel, European Respiratory Journal	2015	1K
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio, The Lancet Advanced Lung DiseaseMedicinePathologyCancer GenomicsMolecular Diagnostics	2016	969
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management David W. Denning, J. Cadranel, Catherine Beigelman‐Aubry, European Respiratory Journal AsthmaDiagnostic MycologyPulmonary PathologyAdvanced Lung DiseaseDiagnosis	2015	949
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, J. Cadranel, The Lancet Oncology Sexual HealthOncologyHiv Viral LoadTreatment And PreventionAntiviral Therapy	2009	549
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Myriam Delaunay, J. Cadranel, Amélie Lusque, European Respiratory Journal	2017	416
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) George R. Blumenschein, Egbert F. Smit, David Planchard, Annals of Oncology Non-small-cell Lung CancerMedicinePharmacologyPathologyCancer Cell Biology	2015	355
Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients Magid Herida, Murielle Mary‐Krause, R. Kaphan, Journal of Clinical Oncology	2003	337
Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases Olivier Lortholary, Marie‐Caroline Meyohas, B. Dupont, The American Journal of Medicine Primary ImmunodeficiencyInvasive AspergillosisMedicinePathologyClinical Mycology	1993	197
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations Julien Mazières, Claire Cropet, Laure Montané, Annals of Oncology	2020	185

Page 1